BTIG Research restated their neutral rating on shares of Oncocyte (NASDAQ:IMDX – Free Report) in a research report released on Wednesday,Benzinga reports.
A number of other research analysts have also commented on the company. Wall Street Zen lowered Oncocyte from a “hold” rating to a “sell” rating in a report on Saturday, October 3rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Oncocyte in a research report on Monday, September 21st. Stephens restated an “equal weight” rating and issued a $4.00 price objective on shares of Oncocyte in a research note on Wednesday. Finally, Needham & Company LLC restated a “buy” rating and issued a $9.00 price objective on shares of Oncocyte in a research note on Tuesday, August 18th. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Oncocyte has a consensus rating of “Hold” and an average price target of $8.33.
View Our Latest Stock Report on Oncocyte
Oncocyte Stock Performance
NASDAQ IMDX opened at $1.59 on Wednesday. Oncocyte has a twelve month low of $1.50 and a twelve month high of $7.51. The stock has a market capitalization of $52.03 million, a PE ratio of -1.27 and a beta of 1.90. The stock has a 50-day simple moving average of $3.15 and a 200 day simple moving average of $4.48.
Oncocyte (NASDAQ:IMDX – Get Free Report) last released its earnings results on Monday, November 16th. The company reported ($0.19) earnings per share (EPS) for the quarter. The business had revenue of $0.56 million during the quarter.
About Oncocyte
Oncocyte Corporation, now known as Insight Molecular Diagnostics, Inc. (NASDAQ: IMDX), is a molecular diagnostics company focused on monitoring organ transplants. Its tests analyze donor-derived cell-free DNA in a transplant recipient’s blood to help assess graft health and identify signs of potential injury or rejection. The company’s VitaGraft tests include assays for kidney and liver transplant monitoring. These laboratory-developed tests are processed through the company’s clinical laboratory and are intended to provide clinicians with information that can complement other aspects of post-transplant care.
Recommended Stories
- Five stocks we like better than Oncocyte
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Receive News & Ratings for Oncocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncocyte and related companies with MarketBeat.com's FREE daily email newsletter.
